Adjunctive Intravenous Ascorbic Acid for Advanced Non-Small Cell Lung Cancer

Study acronym: AIVAA
StatusTerminated
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial terminated Sponsor's reason: Insufficient recruitment Show 5 more changesShow less
    • Final enrollment: 3 participants — 3% of the 90 planned
    • Primary completion date changed from estimate of Oct 1, 2030 to Sep 24, 2026
    • Eligibility criteria expanded, about 12 words
    • Secondary endpoints: details revised at 5 of 8 entries
    • Site details revised
  2. 2 versions Re-verified since Jul 4, 2025, no change to tracked fieldsv6-v7
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v5
  4. Primary completion date: Feb 1, 2030 to Oct 1, 2030
    • Start date: Feb 1, 2024 to Oct 1, 2024
    • Study completion date: Feb 1, 2031 to Oct 1, 2031
    v4
  5. Primary completion date: Jul 1, 2029 to Feb 1, 2030
    • Start date: Jul 1, 2023 to Feb 1, 2024
    • Study completion date: Jul 1, 2030 to Feb 1, 2031
    v3
  6. Secondary endpoints: details revised at 7 of 8 entriesv2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a two arm RCT evaluating the effect of intravenous vitamin C versus placebo in patients with incurable non-small cell lung cancer. Participants in both arms will be receiving platinum doublet chemotherapy with or without concurrent immunotherapy as standard care. We plan to enroll 90 patients over 5 years.
Trial Details
NCT Number NCT05849129
Lead Sponsor The Canadian College of Naturopathic Medicine
Collaborators: Ottawa Hospital Research Institute
Conditions
(from sponsor)		 Lung Cancer
Related terms Lung Neoplasms
Enrollment 3 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov